Search research articles
Contact Us
Filters
Showing results (1-10 of 187) with videos related to
Page
of 19
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 10, 2025
Reply to: Comment on The Study of NRG258: Limitations and Future Directions
Daniela Matei
Expert Opinion on Investigational Drugs
|
August 10, 2007
Novel agents in ovarian cancer
Daniela Matei
The Lancet. Oncology
|
June 18, 2021
Immunotherapy in ovarian cancer: we are not there yet
Emma Barber, Daniela Matei
Cancer Biology & Therapy
|
August 6, 2010
Blockade of FGF signaling: therapeutic promise for ovarian cancer
Mircea Ivan, Daniela Matei
Therapeutics and Clinical Risk Management
|
August 27, 2009
Pegylated liposomal doxorubicin in ovarian cancer
Robert Strother, Daniela Matei
Cancer Treatment Reviews
|
July 19, 2011
Targeting angiogenesis in ovarian cancer
Jordan Schmitt, Daniela Matei
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 19, 2022
Paclitaxel and Carboplatin for Uterine Carcinosarcoma: A Path to Inclusion
Dario R Roque, Daniela Matei
Cancer Research
|
May 9, 2020
Epigenetic Attire in Ovarian Cancer: The Emperor's New Clothes
Daniela Matei, Kenneth P Nephew
The Journal of Reproductive Medicine
|
August 4, 2010
Breast mass in a patient with ovarian cancer: a case report
Suresh Gayathri, Sunil Badve, Daniela Matei
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
May 4, 2013
Tissue transglutaminase regulates β-catenin signaling through a c-Src-dependent mechanism
Salvatore Condello, Liyun Cao, Daniela Matei
Page
of 19
Search research articles
Search
Showing results (1-10 of 187) with videos related to
Sort By:
Page
of 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 10, 2025
Reply to: Comment on The Study of NRG258: Limitations and Future Directions
Daniela Matei
Expert Opinion on Investigational Drugs
|
August 10, 2007
Novel agents in ovarian cancer
Daniela Matei
The Lancet. Oncology
|
June 18, 2021
Immunotherapy in ovarian cancer: we are not there yet
Emma Barber, Daniela Matei
Cancer Biology & Therapy
|
August 6, 2010
Blockade of FGF signaling: therapeutic promise for ovarian cancer
Mircea Ivan, Daniela Matei
Therapeutics and Clinical Risk Management
|
August 27, 2009
Pegylated liposomal doxorubicin in ovarian cancer
Robert Strother, Daniela Matei
Cancer Treatment Reviews
|
July 19, 2011
Targeting angiogenesis in ovarian cancer
Jordan Schmitt, Daniela Matei
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 19, 2022
Paclitaxel and Carboplatin for Uterine Carcinosarcoma: A Path to Inclusion
Dario R Roque, Daniela Matei
Cancer Research
|
May 9, 2020
Epigenetic Attire in Ovarian Cancer: The Emperor's New Clothes
Daniela Matei, Kenneth P Nephew
The Journal of Reproductive Medicine
|
August 4, 2010
Breast mass in a patient with ovarian cancer: a case report
Suresh Gayathri, Sunil Badve, Daniela Matei
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
May 4, 2013
Tissue transglutaminase regulates β-catenin signaling through a c-Src-dependent mechanism
Salvatore Condello, Liyun Cao, Daniela Matei
Page
of 19